A Gene Editing Pioneer Refines Its Focus
Since my last update, Caribou Biosciences has made significant strides in its gene editing research, targeting hematological cancers and autoimmune diseases with its allogeneic therapies. In a strategic move, the company has opted to concentrate its efforts on CAR-T therapies, discontinuing its CAR-NK platform to optimize resources and extend its runway.
As a neutral observer, I have no financial stake in Caribou Biosciences or any other company mentioned in this article. My opinions are my own, and I do not receive compensation for my work beyond what is provided by Seeking Alpha. I have no business ties to any company mentioned, and my goal is to provide an unbiased perspective.
It’s essential to recognize that past performance is not a guarantee of future success. Investment decisions should be made after careful consideration of individual circumstances and risk tolerance. The views expressed in this article are those of the author and may not reflect the opinions of Seeking Alpha as a whole.
Leave a Reply